nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—CYP1A2—Imiquimod—skin cancer	0.163	0.196	CbGbCtD
Ergotamine—ABCB1—Vismodegib—skin cancer	0.0989	0.119	CbGbCtD
Ergotamine—CYP1A2—Vemurafenib—skin cancer	0.0894	0.107	CbGbCtD
Ergotamine—CYP3A4—Imiquimod—skin cancer	0.0855	0.103	CbGbCtD
Ergotamine—CYP3A4—Temozolomide—skin cancer	0.0855	0.103	CbGbCtD
Ergotamine—CYP1A2—Dacarbazine—skin cancer	0.0685	0.0823	CbGbCtD
Ergotamine—CYP3A4—Vismodegib—skin cancer	0.0593	0.0712	CbGbCtD
Ergotamine—ABCB1—Dactinomycin—skin cancer	0.0519	0.0624	CbGbCtD
Ergotamine—CYP3A4—Vemurafenib—skin cancer	0.0468	0.0563	CbGbCtD
Ergotamine—CYP1A2—Fluorouracil—skin cancer	0.0402	0.0483	CbGbCtD
Ergotamine—ABCB1—Docetaxel—skin cancer	0.0268	0.0322	CbGbCtD
Ergotamine—CYP3A4—Docetaxel—skin cancer	0.0161	0.0193	CbGbCtD
Ergotamine—Ischaemia—Imiquimod—skin cancer	0.00984	0.124	CcSEcCtD
Ergotamine—Emotional distress—Fluorouracil—skin cancer	0.00466	0.0586	CcSEcCtD
Ergotamine—SLC6A2—nerve—skin cancer	0.00264	0.0497	CbGeAlD
Ergotamine—HTR2A—hindlimb—skin cancer	0.00261	0.0491	CbGeAlD
Ergotamine—HTR1B—blood vessel—skin cancer	0.00259	0.0487	CbGeAlD
Ergotamine—Myalgia—Vismodegib—skin cancer	0.00254	0.0319	CcSEcCtD
Ergotamine—HTR1D—blood vessel—skin cancer	0.00251	0.0472	CbGeAlD
Ergotamine—DRD2—nerve—skin cancer	0.00241	0.0453	CbGeAlD
Ergotamine—Numbness—Fluorouracil—skin cancer	0.00239	0.0301	CcSEcCtD
Ergotamine—Sensory loss—Fluorouracil—skin cancer	0.00229	0.0288	CcSEcCtD
Ergotamine—HTR2A—appendage—skin cancer	0.00224	0.0421	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00222	0.0278	CcSEcCtD
Ergotamine—Pain—Vismodegib—skin cancer	0.00208	0.0261	CcSEcCtD
Ergotamine—HTR1F—head—skin cancer	0.00191	0.0359	CbGeAlD
Ergotamine—Asthenia—Vismodegib—skin cancer	0.00174	0.0219	CcSEcCtD
Ergotamine—Pruritus—Vismodegib—skin cancer	0.00172	0.0216	CcSEcCtD
Ergotamine—HTR1E—head—skin cancer	0.00166	0.0311	CbGeAlD
Ergotamine—ADRA1D—epithelium—skin cancer	0.00163	0.0307	CbGeAlD
Ergotamine—HTR2A—nerve—skin cancer	0.00159	0.0298	CbGeAlD
Ergotamine—Myalgia—Vemurafenib—skin cancer	0.00157	0.0197	CcSEcCtD
Ergotamine—Vomiting—Vismodegib—skin cancer	0.00155	0.0194	CcSEcCtD
Ergotamine—Nausea—Vismodegib—skin cancer	0.00144	0.0182	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00137	0.0172	CcSEcCtD
Ergotamine—Hypertension—Imiquimod—skin cancer	0.00136	0.017	CcSEcCtD
Ergotamine—HTR2A—endothelium—skin cancer	0.00135	0.0254	CbGeAlD
Ergotamine—Myalgia—Imiquimod—skin cancer	0.00134	0.0168	CcSEcCtD
Ergotamine—HTR1D—connective tissue—skin cancer	0.00129	0.0242	CbGeAlD
Ergotamine—Hypoaesthesia—Bleomycin—skin cancer	0.00127	0.016	CcSEcCtD
Ergotamine—Tachycardia—Imiquimod—skin cancer	0.00125	0.0157	CcSEcCtD
Ergotamine—HTR2A—blood vessel—skin cancer	0.00125	0.0234	CbGeAlD
Ergotamine—ADRA1D—female reproductive system—skin cancer	0.00121	0.0228	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00117	0.0147	CcSEcCtD
Ergotamine—CYP1A2—nipple—skin cancer	0.00115	0.0217	CbGeAlD
Ergotamine—Paraesthesia—Imiquimod—skin cancer	0.00115	0.0145	CcSEcCtD
Ergotamine—Pain—Imiquimod—skin cancer	0.0011	0.0138	CcSEcCtD
Ergotamine—HTR2B—skin of body—skin cancer	0.00108	0.0203	CbGeAlD
Ergotamine—Asthenia—Vemurafenib—skin cancer	0.00108	0.0135	CcSEcCtD
Ergotamine—Hypoaesthesia—Temozolomide—skin cancer	0.00108	0.0135	CcSEcCtD
Ergotamine—Pruritus—Vemurafenib—skin cancer	0.00106	0.0134	CcSEcCtD
Ergotamine—ADRA2A—nipple—skin cancer	0.00106	0.0199	CbGeAlD
Ergotamine—ADRA1B—head—skin cancer	0.00104	0.0195	CbGeAlD
Ergotamine—ADRA1D—head—skin cancer	0.00101	0.0191	CbGeAlD
Ergotamine—Hypoaesthesia—Fluorouracil—skin cancer	0.000991	0.0125	CcSEcCtD
Ergotamine—Vomiting—Vemurafenib—skin cancer	0.000955	0.012	CcSEcCtD
Ergotamine—Myalgia—Bleomycin—skin cancer	0.000949	0.0119	CcSEcCtD
Ergotamine—ADRA1A—epithelium—skin cancer	0.000939	0.0176	CbGeAlD
Ergotamine—HTR1B—female reproductive system—skin cancer	0.000938	0.0176	CbGeAlD
Ergotamine—Asthenia—Imiquimod—skin cancer	0.000919	0.0116	CcSEcCtD
Ergotamine—HTR1D—female reproductive system—skin cancer	0.000908	0.0171	CbGeAlD
Ergotamine—Pruritus—Imiquimod—skin cancer	0.000906	0.0114	CcSEcCtD
Ergotamine—HTR2C—female reproductive system—skin cancer	0.000899	0.0169	CbGeAlD
Ergotamine—Nausea—Vemurafenib—skin cancer	0.000892	0.0112	CcSEcCtD
Ergotamine—HTR2A—neck—skin cancer	0.000892	0.0168	CbGeAlD
Ergotamine—Myalgia—Dactinomycin—skin cancer	0.000885	0.0111	CcSEcCtD
Ergotamine—Vertigo—Temozolomide—skin cancer	0.000845	0.0106	CcSEcCtD
Ergotamine—HTR2B—female reproductive system—skin cancer	0.000844	0.0159	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000829	0.0104	CcSEcCtD
Ergotamine—Paraesthesia—Bleomycin—skin cancer	0.000817	0.0103	CcSEcCtD
Ergotamine—ABCB1—blood vessel—skin cancer	0.000817	0.0154	CbGeAlD
Ergotamine—Vomiting—Imiquimod—skin cancer	0.000815	0.0102	CcSEcCtD
Ergotamine—Hypertension—Temozolomide—skin cancer	0.000812	0.0102	CcSEcCtD
Ergotamine—Myalgia—Temozolomide—skin cancer	0.000801	0.0101	CcSEcCtD
Ergotamine—HTR1B—head—skin cancer	0.000783	0.0147	CbGeAlD
Ergotamine—Pain—Bleomycin—skin cancer	0.000778	0.00978	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000773	0.00972	CcSEcCtD
Ergotamine—Nausea—Imiquimod—skin cancer	0.000761	0.00957	CcSEcCtD
Ergotamine—HTR1D—head—skin cancer	0.000758	0.0143	CbGeAlD
Ergotamine—ADRA2A—connective tissue—skin cancer	0.000752	0.0141	CbGeAlD
Ergotamine—HTR2C—head—skin cancer	0.000751	0.0141	CbGeAlD
Ergotamine—SLC6A2—female reproductive system—skin cancer	0.00075	0.0141	CbGeAlD
Ergotamine—Myalgia—Fluorouracil—skin cancer	0.000738	0.00928	CcSEcCtD
Ergotamine—Pain—Dactinomycin—skin cancer	0.000726	0.00912	CcSEcCtD
Ergotamine—ADRA1A—lymphoid tissue—skin cancer	0.000723	0.0136	CbGeAlD
Ergotamine—Hypoaesthesia—Docetaxel—skin cancer	0.000715	0.00899	CcSEcCtD
Ergotamine—HTR2B—head—skin cancer	0.000705	0.0133	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000699	0.00879	CcSEcCtD
Ergotamine—Tachycardia—Fluorouracil—skin cancer	0.00069	0.00868	CcSEcCtD
Ergotamine—Paraesthesia—Temozolomide—skin cancer	0.000689	0.00867	CcSEcCtD
Ergotamine—Pain—Temozolomide—skin cancer	0.000657	0.00825	CcSEcCtD
Ergotamine—Asthenia—Bleomycin—skin cancer	0.000653	0.00821	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000644	0.0081	CcSEcCtD
Ergotamine—Pruritus—Bleomycin—skin cancer	0.000644	0.00809	CcSEcCtD
Ergotamine—HTR2A—connective tissue—skin cancer	0.000639	0.012	CbGeAlD
Ergotamine—Paraesthesia—Fluorouracil—skin cancer	0.000635	0.00798	CcSEcCtD
Ergotamine—HTR1A—head—skin cancer	0.000632	0.0119	CbGeAlD
Ergotamine—SLC6A2—head—skin cancer	0.000627	0.0118	CbGeAlD
Ergotamine—ADRA2A—mammalian vulva—skin cancer	0.000619	0.0116	CbGeAlD
Ergotamine—Asthenia—Dactinomycin—skin cancer	0.000609	0.00766	CcSEcCtD
Ergotamine—HTR2A—epithelium—skin cancer	0.000607	0.0114	CbGeAlD
Ergotamine—Pain—Fluorouracil—skin cancer	0.000605	0.0076	CcSEcCtD
Ergotamine—ADRA1A—head—skin cancer	0.000583	0.011	CbGeAlD
Ergotamine—Vomiting—Bleomycin—skin cancer	0.000579	0.00727	CcSEcCtD
Ergotamine—DRD2—head—skin cancer	0.000571	0.0107	CbGeAlD
Ergotamine—Asthenia—Temozolomide—skin cancer	0.000551	0.00692	CcSEcCtD
Ergotamine—Pruritus—Temozolomide—skin cancer	0.000543	0.00683	CcSEcCtD
Ergotamine—Nausea—Bleomycin—skin cancer	0.000541	0.0068	CcSEcCtD
Ergotamine—Hypertension—Docetaxel—skin cancer	0.00054	0.00679	CcSEcCtD
Ergotamine—Vomiting—Dactinomycin—skin cancer	0.00054	0.00678	CcSEcCtD
Ergotamine—Myalgia—Docetaxel—skin cancer	0.000533	0.0067	CcSEcCtD
Ergotamine—ADRA2A—female reproductive system—skin cancer	0.00053	0.00997	CbGeAlD
Ergotamine—Nausea—Dactinomycin—skin cancer	0.000504	0.00634	CcSEcCtD
Ergotamine—Pruritus—Fluorouracil—skin cancer	0.0005	0.00629	CcSEcCtD
Ergotamine—Tachycardia—Docetaxel—skin cancer	0.000498	0.00626	CcSEcCtD
Ergotamine—HTR2B—lymph node—skin cancer	0.000494	0.00928	CbGeAlD
Ergotamine—Vomiting—Temozolomide—skin cancer	0.000488	0.00614	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000465	0.00585	CcSEcCtD
Ergotamine—Paraesthesia—Docetaxel—skin cancer	0.000458	0.00576	CcSEcCtD
Ergotamine—Nausea—Temozolomide—skin cancer	0.000456	0.00573	CcSEcCtD
Ergotamine—HTR2A—female reproductive system—skin cancer	0.000451	0.00848	CbGeAlD
Ergotamine—Vomiting—Fluorouracil—skin cancer	0.00045	0.00565	CcSEcCtD
Ergotamine—ADRA2A—head—skin cancer	0.000443	0.00833	CbGeAlD
Ergotamine—SLC6A2—lymph node—skin cancer	0.000439	0.00825	CbGeAlD
Ergotamine—Pain—Docetaxel—skin cancer	0.000437	0.00549	CcSEcCtD
Ergotamine—Nausea—Fluorouracil—skin cancer	0.00042	0.00528	CcSEcCtD
Ergotamine—CYP3A4—female reproductive system—skin cancer	0.000417	0.00785	CbGeAlD
Ergotamine—ABCB1—epithelium—skin cancer	0.000398	0.00748	CbGeAlD
Ergotamine—HTR2A—head—skin cancer	0.000377	0.00708	CbGeAlD
Ergotamine—Asthenia—Docetaxel—skin cancer	0.000366	0.0046	CcSEcCtD
Ergotamine—Pruritus—Docetaxel—skin cancer	0.000361	0.00454	CcSEcCtD
Ergotamine—ABCB1—mammalian vulva—skin cancer	0.000345	0.00649	CbGeAlD
Ergotamine—Vomiting—Docetaxel—skin cancer	0.000325	0.00408	CcSEcCtD
Ergotamine—ADRA2A—lymph node—skin cancer	0.00031	0.00583	CbGeAlD
Ergotamine—ABCB1—lymphoid tissue—skin cancer	0.000306	0.00576	CbGeAlD
Ergotamine—Nausea—Docetaxel—skin cancer	0.000303	0.00381	CcSEcCtD
Ergotamine—ABCB1—female reproductive system—skin cancer	0.000295	0.00555	CbGeAlD
Ergotamine—ABCB1—head—skin cancer	0.000247	0.00464	CbGeAlD
Ergotamine—ABCB1—lymph node—skin cancer	0.000173	0.00325	CbGeAlD
Ergotamine—HTR2A—Signaling Pathways—SUFU—skin cancer	2.44e-05	0.000695	CbGpPWpGaD
Ergotamine—DRD2—Circadian rythm related genes—TP53—skin cancer	2.42e-05	0.00069	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SUFU—skin cancer	2.39e-05	0.000681	CbGpPWpGaD
Ergotamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.38e-05	0.000678	CbGpPWpGaD
Ergotamine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.38e-05	0.000678	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MC1R—skin cancer	2.38e-05	0.000677	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—FOXO4—skin cancer	2.36e-05	0.000671	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—SMO—skin cancer	2.35e-05	0.000668	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PTCH1—skin cancer	2.35e-05	0.000668	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—GLI1—skin cancer	2.34e-05	0.000667	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—TERT—skin cancer	2.32e-05	0.000661	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—FOXO4—skin cancer	2.31e-05	0.000657	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PTGER4—skin cancer	2.28e-05	0.00065	CbGpPWpGaD
Ergotamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.28e-05	0.000649	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—SHH—skin cancer	2.23e-05	0.000636	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SUFU—skin cancer	2.22e-05	0.000633	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—RASA1—skin cancer	2.22e-05	0.000632	CbGpPWpGaD
Ergotamine—DRD2—Circadian rythm related genes—IL6—skin cancer	2.22e-05	0.000631	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—FOXO4—skin cancer	2.17e-05	0.000617	CbGpPWpGaD
Ergotamine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.16e-05	0.000615	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—SHH—skin cancer	2.16e-05	0.000614	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—SHH—skin cancer	2.15e-05	0.000611	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—RASA1—skin cancer	2.14e-05	0.00061	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—RASA1—skin cancer	2.13e-05	0.000607	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—SMO—skin cancer	2.12e-05	0.000603	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PTCH1—skin cancer	2.12e-05	0.000603	CbGpPWpGaD
Ergotamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.12e-05	0.000602	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—NRAS—skin cancer	2.07e-05	0.00059	CbGpPWpGaD
Ergotamine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.07e-05	0.000589	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CSPG4—skin cancer	2.06e-05	0.000587	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PTGER4—skin cancer	2.06e-05	0.000587	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—SHH—skin cancer	2.05e-05	0.000585	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PTCH1—skin cancer	2.04e-05	0.000582	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—SMO—skin cancer	2.04e-05	0.000582	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PLIN2—skin cancer	2.04e-05	0.000581	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—RASA1—skin cancer	2.04e-05	0.000581	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PTCH1—skin cancer	2.03e-05	0.000579	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—SMO—skin cancer	2.03e-05	0.000579	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—ENO2—skin cancer	2.03e-05	0.000577	CbGpPWpGaD
Ergotamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.02e-05	0.000576	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—FOXO4—skin cancer	2.02e-05	0.000574	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PTGER4—skin cancer	1.99e-05	0.000566	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PTGER4—skin cancer	1.98e-05	0.000564	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—NRAS—skin cancer	1.96e-05	0.000557	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—BRAF—skin cancer	1.95e-05	0.000555	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PTCH1—skin cancer	1.95e-05	0.000554	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—SMO—skin cancer	1.95e-05	0.000554	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PTGER4—skin cancer	1.9e-05	0.000539	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SHH—skin cancer	1.89e-05	0.000539	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—RASA1—skin cancer	1.88e-05	0.000536	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SHH—skin cancer	1.86e-05	0.00053	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—RASA1—skin cancer	1.85e-05	0.000527	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—BRAF—skin cancer	1.84e-05	0.000523	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SHH—skin cancer	1.82e-05	0.000519	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—FOXO4—skin cancer	1.82e-05	0.000518	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—RASA1—skin cancer	1.81e-05	0.000516	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PTCH1—skin cancer	1.79e-05	0.000511	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SMO—skin cancer	1.79e-05	0.000511	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—NRAS—skin cancer	1.79e-05	0.000508	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—KRAS—skin cancer	1.78e-05	0.000508	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PTCH1—skin cancer	1.77e-05	0.000503	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SMO—skin cancer	1.77e-05	0.000503	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—FOXO4—skin cancer	1.76e-05	0.0005	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.76e-05	0.0005	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—FOXO4—skin cancer	1.75e-05	0.000498	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PTGER4—skin cancer	1.75e-05	0.000497	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SMO—skin cancer	1.73e-05	0.000492	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PTCH1—skin cancer	1.73e-05	0.000492	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PTGER4—skin cancer	1.72e-05	0.000489	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SHH—skin cancer	1.69e-05	0.000482	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—RASA1—skin cancer	1.68e-05	0.000479	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—KRAS—skin cancer	1.68e-05	0.000479	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PTGER4—skin cancer	1.68e-05	0.000479	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—FOXO4—skin cancer	1.67e-05	0.000477	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CSPG4—skin cancer	1.65e-05	0.000469	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PTCH1—skin cancer	1.61e-05	0.000457	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SMO—skin cancer	1.61e-05	0.000457	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PLIN2—skin cancer	1.58e-05	0.000449	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TERT—skin cancer	1.57e-05	0.000448	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PTGER4—skin cancer	1.56e-05	0.000445	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.56e-05	0.000445	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—FOXO4—skin cancer	1.54e-05	0.000439	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TERT—skin cancer	1.54e-05	0.000439	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—KRAS—skin cancer	1.54e-05	0.000437	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—FOXO4—skin cancer	1.52e-05	0.000432	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—HRAS—skin cancer	1.52e-05	0.000432	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—FOXO4—skin cancer	1.49e-05	0.000423	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—IL6—skin cancer	1.45e-05	0.000413	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TERT—skin cancer	1.45e-05	0.000412	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—HRAS—skin cancer	1.43e-05	0.000407	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ENO2—skin cancer	1.4e-05	0.000399	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—FOXO4—skin cancer	1.38e-05	0.000393	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—IL6—skin cancer	1.37e-05	0.00039	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—TP53—skin cancer	1.37e-05	0.000389	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—NRAS—skin cancer	1.35e-05	0.000386	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TERT—skin cancer	1.35e-05	0.000383	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—NRAS—skin cancer	1.33e-05	0.000378	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—HRAS—skin cancer	1.31e-05	0.000372	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—NRAS—skin cancer	1.3e-05	0.00037	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CSPG4—skin cancer	1.27e-05	0.000362	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—BRAF—skin cancer	1.25e-05	0.000355	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—NRAS—skin cancer	1.23e-05	0.000349	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—BRAF—skin cancer	1.22e-05	0.000347	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—NRAS—skin cancer	1.22e-05	0.000347	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TERT—skin cancer	1.22e-05	0.000346	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—ERCC2—skin cancer	1.18e-05	0.000335	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TERT—skin cancer	1.17e-05	0.000334	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TERT—skin cancer	1.17e-05	0.000333	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—KRAS—skin cancer	1.17e-05	0.000332	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—NRAS—skin cancer	1.16e-05	0.000329	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—BRAF—skin cancer	1.15e-05	0.000326	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—KRAS—skin cancer	1.14e-05	0.000325	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—NRAS—skin cancer	1.14e-05	0.000323	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ENO2—skin cancer	1.12e-05	0.000319	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TERT—skin cancer	1.12e-05	0.000318	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—KRAS—skin cancer	1.12e-05	0.000318	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—BRAF—skin cancer	1.07e-05	0.000304	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—KRAS—skin cancer	1.05e-05	0.0003	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—KRAS—skin cancer	1.05e-05	0.000299	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—TP53—skin cancer	1.04e-05	0.000295	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TERT—skin cancer	1.03e-05	0.000293	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.02e-05	0.000292	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TERT—skin cancer	1.01e-05	0.000289	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—KRAS—skin cancer	9.95e-06	0.000283	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TERT—skin cancer	9.93e-06	0.000283	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—HRAS—skin cancer	9.91e-06	0.000282	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—NRAS—skin cancer	9.89e-06	0.000282	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—NRAS—skin cancer	9.84e-06	0.00028	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—KRAS—skin cancer	9.77e-06	0.000278	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—HRAS—skin cancer	9.7e-06	0.000276	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—BRAF—skin cancer	9.63e-06	0.000274	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—HRAS—skin cancer	9.5e-06	0.00027	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—NRAS—skin cancer	9.42e-06	0.000268	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—TP53—skin cancer	9.37e-06	0.000267	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—BRAF—skin cancer	9.3e-06	0.000265	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—IL6—skin cancer	9.29e-06	0.000264	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—BRAF—skin cancer	9.25e-06	0.000263	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TERT—skin cancer	9.23e-06	0.000263	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—IL6—skin cancer	9.09e-06	0.000259	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—HRAS—skin cancer	8.96e-06	0.000255	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—HRAS—skin cancer	8.92e-06	0.000254	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—BRAF—skin cancer	8.86e-06	0.000252	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—TP53—skin cancer	8.84e-06	0.000252	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—KRAS—skin cancer	8.82e-06	0.000251	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.75e-06	0.000249	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—NRAS—skin cancer	8.69e-06	0.000247	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ENO2—skin cancer	8.64e-06	0.000246	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—IL6—skin cancer	8.58e-06	0.000244	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—NRAS—skin cancer	8.55e-06	0.000243	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—IL6—skin cancer	8.54e-06	0.000243	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—KRAS—skin cancer	8.51e-06	0.000242	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—KRAS—skin cancer	8.47e-06	0.000241	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—HRAS—skin cancer	8.45e-06	0.000241	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	8.37e-06	0.000238	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—HRAS—skin cancer	8.3e-06	0.000236	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—BRAF—skin cancer	8.16e-06	0.000232	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ERCC2—skin cancer	8.14e-06	0.000232	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—KRAS—skin cancer	8.11e-06	0.000231	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—IL6—skin cancer	8.09e-06	0.00023	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—BRAF—skin cancer	8.03e-06	0.000229	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—IL6—skin cancer	7.95e-06	0.000226	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—BRAF—skin cancer	7.87e-06	0.000224	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—NRAS—skin cancer	7.83e-06	0.000223	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	7.78e-06	0.000221	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—NRAS—skin cancer	7.67e-06	0.000218	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—HRAS—skin cancer	7.5e-06	0.000213	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—KRAS—skin cancer	7.48e-06	0.000213	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—KRAS—skin cancer	7.36e-06	0.000209	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—BRAF—skin cancer	7.31e-06	0.000208	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—HRAS—skin cancer	7.24e-06	0.000206	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—NRAS—skin cancer	7.21e-06	0.000205	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	7.2e-06	0.000205	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—HRAS—skin cancer	7.2e-06	0.000205	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—IL6—skin cancer	7.18e-06	0.000204	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTGS2—skin cancer	7.06e-06	0.000201	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—IL6—skin cancer	6.93e-06	0.000197	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—HRAS—skin cancer	6.89e-06	0.000196	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—IL6—skin cancer	6.89e-06	0.000196	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—KRAS—skin cancer	6.74e-06	0.000192	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—NRAS—skin cancer	6.71e-06	0.000191	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	6.69e-06	0.00019	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—KRAS—skin cancer	6.6e-06	0.000188	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—IL6—skin cancer	6.6e-06	0.000188	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ERCC2—skin cancer	6.5e-06	0.000185	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HRAS—skin cancer	6.35e-06	0.000181	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—HRAS—skin cancer	6.25e-06	0.000178	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—KRAS—skin cancer	6.2e-06	0.000177	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	6.12e-06	0.000174	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—skin cancer	6.08e-06	0.000173	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NRAS—skin cancer	6.05e-06	0.000172	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—skin cancer	5.99e-06	0.000171	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—skin cancer	5.98e-06	0.00017	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—skin cancer	5.87e-06	0.000167	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—skin cancer	5.86e-06	0.000167	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NRAS—skin cancer	5.84e-06	0.000166	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NRAS—skin cancer	5.81e-06	0.000165	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—KRAS—skin cancer	5.77e-06	0.000164	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HRAS—skin cancer	5.73e-06	0.000163	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	5.69e-06	0.000162	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HRAS—skin cancer	5.61e-06	0.00016	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NRAS—skin cancer	5.57e-06	0.000158	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—skin cancer	5.51e-06	0.000157	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—skin cancer	5.49e-06	0.000156	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—skin cancer	5.44e-06	0.000155	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—skin cancer	5.37e-06	0.000153	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HRAS—skin cancer	5.27e-06	0.00015	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—KRAS—skin cancer	5.21e-06	0.000148	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NRAS—skin cancer	5.13e-06	0.000146	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—skin cancer	5.13e-06	0.000146	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NRAS—skin cancer	5.05e-06	0.000144	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—skin cancer	5.05e-06	0.000144	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—KRAS—skin cancer	5.03e-06	0.000143	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ERCC2—skin cancer	5.02e-06	0.000143	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—KRAS—skin cancer	5e-06	0.000142	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NRAS—skin cancer	4.94e-06	0.000141	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HRAS—skin cancer	4.91e-06	0.00014	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—skin cancer	4.88e-06	0.000139	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—KRAS—skin cancer	4.79e-06	0.000136	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—skin cancer	4.7e-06	0.000134	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—skin cancer	4.63e-06	0.000132	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NRAS—skin cancer	4.59e-06	0.000131	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—skin cancer	4.47e-06	0.000127	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—skin cancer	4.45e-06	0.000127	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HRAS—skin cancer	4.43e-06	0.000126	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—KRAS—skin cancer	4.42e-06	0.000126	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—KRAS—skin cancer	4.35e-06	0.000124	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HRAS—skin cancer	4.28e-06	0.000122	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—skin cancer	4.26e-06	0.000121	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—KRAS—skin cancer	4.25e-06	0.000121	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HRAS—skin cancer	4.25e-06	0.000121	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—skin cancer	4.24e-06	0.000121	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—skin cancer	4.09e-06	0.000116	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HRAS—skin cancer	4.07e-06	0.000116	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—skin cancer	4.07e-06	0.000116	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—KRAS—skin cancer	3.95e-06	0.000113	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—skin cancer	3.92e-06	0.000112	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—skin cancer	3.9e-06	0.000111	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—skin cancer	3.9e-06	0.000111	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—skin cancer	3.86e-06	0.00011	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—skin cancer	3.78e-06	0.000108	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HRAS—skin cancer	3.75e-06	0.000107	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HRAS—skin cancer	3.69e-06	0.000105	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HRAS—skin cancer	3.62e-06	0.000103	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—skin cancer	3.59e-06	0.000102	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—skin cancer	3.53e-06	0.000101	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—skin cancer	3.51e-06	0.0001	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—skin cancer	3.46e-06	9.85e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HRAS—skin cancer	3.36e-06	9.56e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—skin cancer	3.22e-06	9.15e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—skin cancer	3.01e-06	8.56e-05	CbGpPWpGaD
